-+ 0.00%
-+ 0.00%
-+ 0.00%

iMDx GraftAssure Assay Guides Use of Potentially Kidney-Graft-Saving Drug in New Lancet Group Publication

Barchart·07/23/2026 07:00:00
Listen to the news

NASHVILLE, Tenn., July 23, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) ("iMDx") today highlighted the publication of a new study in The Lancet Regional Health – Europe, part of the Lancet Group, demonstrating the potential role of donor-derived cell-free DNA (dd-cfDNA) monitoring to help guide treatment decisions for kidney transplant patients.

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.